Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

By sjmartinez • May 19, 2025

Krebs MG, Cho BC, Hiret S, Han JY, Lee KH, Llácer Pérez C, De Braud F, Haura EB, Sanborn RE, Yang JC, Shu CA, Goto K, Nishio M, Zhao J, Wang Z, Tomasini P, Felip E, Goldman JW, Ou SI, Boyer M, Gao G, Qu S, Curtin JC, Lyu X, Schnepp RW, Kim P, Thayu M, Knoblauch RE, Lorenzini P, Baig M, Spira AI, Leighl NB. Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study. J Thorac Oncol. 2025 May 16:S1556-0864(25)00720-8. doi: 10.1016/j.jtho.2025.05.012. Epub ahead of print. PMID: 40383434.

Tags: advanced non-small cell lung cancer, amivantamab, CHRYSALIS, Hematology/Oncology, MET exon 14 skipping mutation, prior MET therapies, Publications

Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease

Prueksapraopong C, Fernandes A, Campo Fernandez B, Roy S, Hollis RP, Habtemariam B, Pellin D, Ceoldo G, Lin TY, Dang TT, Cornetta K, Romero Z,[...]

Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic Breast Cancer: A Brief Report of a Clinical Trial

Henneghan A, Wertheimer J, Kim S, Gresham G, Shirazipour CH, Jones B, Asher A. Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic[...]

Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia

Jang J, Nold T, Marshalek JP, Matthiesen J, Tomassetti S. Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia. J Oncol[...]